Open Access

2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations

logo

Date: 11 July 2020
Journal: European Heart Journal - Cardiovascular Pharmacotherapy , Volume 7 , Issue 4 , Pages 324 - 333
Authors: M. Zeitouni , P. Sabouret , M. Kerneis , J. Silvain , J. Collet , E. Bruckert , G. Montalescot

ESC Journals

Abstract

In 2019, the European Society of Cardiology and European Atherosclerosis Society released a new guideline document with substantial changes regarding the assessment of cardiovascular risk and treatments. The update of high-risk criteria and categories led to a better detection and primary prevention of patients at risk of a first cardiovascular event. Nonetheless, additional efforts are needed for a better inclusion of risk modifiers, especially specific to women, to improve risk stratification and direct primary prevention. Eventually, we discuss how these new guidelines implement PCSK9 inhibitors for very high-risk individuals and the evidence supporting new low-density lipoprotein cholesterol goals below, such as 55 and 40 mg/dL.

Page viewed 1 times

About the contributors

Michel Zeitouni

Role: Author

Pierre Sabouret

Role: Author

Mathieu Kerneis

Role: Author